CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (1,865,474)	$ (1,589,260)
Stock option compensation to employees and directors	214,427	259,737
Stock option compensation to consultants	52,546
Common stock issued to consultants	15,002	17,811
Depreciation of property and equipment	4,391	10,505
Amortization of patents	81,324	81,324
Accretion of interest on patent acquisition obligations to interest expense		141,299
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee	64,656
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(103,930)	93,480
Accounts payable	(63,399)	167,453
Accrued expenses	260,464	87,738
Net cash used in operating activities	(1,339,993)	(729,913)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(1,250,000)
Proceeds from maturities of short-term investments in certificates of deposit	2,100,000	150,000
Purchase of property and equipment	(2,518)	(14,121)
Net cash provided by investing activities	847,482	135,879
Cash flows from financing activities:
Redemption of convertible preferred stock		(500,000)
Proceeds from exercise of employee stock options		5,665
Net cash used in by financing activities		(494,335)
Net decrease in cash and cash equivalents	(492,511)	(1,088,369)
Cash and cash equivalents at beginning of period	3,339,374	2,488,323
Cash and cash equivalents at end of period	2,846,863	1,399,954
Supplemental disclosure of non-cash financing activities:
Redemption of Series A convertible preferred stock into secured debenture (Note 6)		$ (3,000,000)